Clinical Research Institute

Medford, Oregon 97504

0 studies enrolling now · 2 studies all time

What they study most

Atopic Dermatitis

Studies at this site

• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. — Completed